. 2022 Sep 7;2022:4624311. doi: 10.1155/2022/4624311

Table 1.

Summary of a randomized clinical trial of CHM.

Prescription	Design	Sample size	Interventions	Main outcomes	References
Gushen Antai pill	RCT	83	Treatment group: estradiol valerate + Gushen Antai pill	1. Total efficiency: treatment group—84.85% (28/33); control group—68.00% (34/50)	[29]
Gushen Antai pill	RCT	83	Control group: estradiol valerate	2. Endometrial thickness after treatment: treatment group—0.73 ± 0.16 mm; control group—0.88 ± 0.18 mm	[29]

Bushen Huoxue recipe	RCT	60	Treatment group: estradiol valerate + Bushen Huoxue recipe	1. Pregnancy rate: treatment group—43.3% (13/30); control group—26.7 (8/30)	[30]
Bushen Huoxue recipe	RCT	60	Control group: estradiol valerate	2. Endometrial thickness after treatment: treatment group—9.6 ± 1.0 mm; control group—8.2 ± 0.4 mm	[30]

Bushen Yanggong decoction	RCT	120	Treatment group: Femoston + Bushen Yanggong decoction	1. Pregnancy rate: treatment group—53.33% (32/60); control group—31.67% (19/60)	[31]
Bushen Yanggong decoction	RCT	120	Control group: Femoston	2. Endometrial thickness after treatment: treatment group—8.19 ± 0.83 mm; control group—7.17 ± 0.82 mm	[31]

Bubao decoction	RCT	115	Treatment group: Bubao decoction + aspirin enteric-coated aspirin group	1. Clinical pregnancy rate: treatment group—47.62%; aspirin group—32.56%	[34]
Bubao decoction	RCT	115	Control group	2. Endometrial thickness after treatment: treatment group—10.65 ±3.03 mm; aspirin group—8.87 ± 2.50 mm	[34]

Danyu decoction	RCT	50	Treatment group: Danyu decoction	1. Pregnancy rate: treatment group—60%; control group—28%	[37]
			Control group: vitamin E capsule	2. The rate of type A endometrium: treatment group—84%; control group—68%
			Control group: vitamin E capsule	3. Treatment group: RI—0.55 ± 0.08; PI—1.83 ± 0.61; control group: RI—0.64 ± 0.16; PI—2.19 ± 0.54

Jieyuyubao pills	RCT	107	Treatment group: Jieyuyubao pills + clomiphene citrate	1. Pregnancy rate: treatment group—24.07%; control group—11.32%	[38]
			Treatment group: Jieyuyubao pills + clomiphene citrate	2. The rate of type A endometrium: treatment group—53.7%; control group—35.8%
			Control group: clomiphene citrate	3. Symptom scores: treatment group—2.1 ± 0.6; control group—5.1 ± 0.6

Erzhi Tiangui granule	RCT	66	Treatment group: Erzhi Tiangui granule + gonadotropin therapy	1. Clinical pregnancy rate: treatment group—54.55% (18/33); control group: 30.30% (10/33)	[39]
Erzhi Tiangui granule	RCT	66	Control group: gonadotropin therapy + placebo granules	2. Endometrial DNMT1 expression: treatment group—3.31 ± 0.46; control group—2.97 ± 0.49	[39]

Yulin Zhuyun prescription	RCT	150	Combine group: Yulin Zhuyun prescription + clomifene citrate capsules	1. Clinical pregnancy rate: combine group—59.1% (26/44); CHM group—44.2% (19/43); Western medicine group—26.8% (11/41)	[40]
			CHM group: Yulin Zhuyun prescription	2. Integrin αvβ3: combine group—13.1 ± 2.67; CHM group—13.82 ± 2.04; Western medicine group—7.05 ± 1.37
			Western medicine group: Clomifene citrate capsules	3. GLUT4: combine group—146.82 ± 21.84; CHM group—113.64 ± 15.62; Western medicine group—112.92 ± 18.54

Kuntai capsule	RCT	71	Treatment group: Kuntai capsule + clomiphene	1. Pregnancy rate: treatment group—25% (9/36); control group—11.4% (4/35)	[41]
Kuntai capsule	RCT	71	Control group: placebo + clomiphene	2. Integrin β3: treatment group—1.78 ± 0.226; control group—1.46 ± 0.252	[41]

Wenjing Quyu prescription	RCT	72	Treatment group: Wenjing Quyu prescription + Gn + HCG	1. Pregnancy rate: treatment group—59.38% (19/32); control group—12.96% (7/24)	[45]
Wenjing Quyu prescription	RCT	72	Control group: Gn + HCG	2. Covered pinopode area: treatment group—>50%; control group—<20%	[45]

Huayu Xiaozheng prescription	RCT	60	Treatment group: Huayu Xiaozheng prescription + urofollicle-stimulating hormone + chorionic gonadotropin + letrozole	1. Pregnancy rate: treatment group—60% (18/30); control group—33.33% (10/30)	[52]
			Control group: urofollicle-stimulating hormone + chorionic gonadotropin + letrozole	2. Uterine volume: treatment group—100.27 ± 2.13 cm³; control group—102.47 ± 3.90 cm³
				3. Endometrial thickness after treatment: treatment group—9.89 ± 044 mm; control group—8.04 ± 1.28 mm

Yishen Sanjie Quyu decoction	RCT	102	Treatment group: Yishen Sanjie Quyu decoction	1. Uterine volume: treatment group—95.46 ± 3.21 cm³; control group—105.44 ± 4.23 cm³	[54]
Yishen Sanjie Quyu decoction	RCT	102	Control group: Sanjie Zhentong capsule	2. Symptom scores: treatment group—5.34 ± 1.46; control group—11.21 ± 2.01	[54]

Wenjing Yangxue decoction	RCT	70	Treatment group: Wenjing Yangxue decoction + dydrogesterone tablets + moxibustion	1. Uterine volume: treatment group—136.47 ± 23.71 cm³; control group—152.38 ± 39.67 cm³	[55]
Wenjing Yangxue decoction	RCT	70	Control group: dydrogesterone tablets + moxibustion	2. RI : treatment group—0.63 ± 0.07; control group—0.66 ± 0.05	[55]

Penning granules	RCT	58	Treatment group: Penning granules	1. Pregnancy rate: treatment group—54.55% (18/33); control group—20% (1/25)	[58]
			Control group: levofloxacin + metronidazole tablets	2. CD38 : treatment group—8.89 ± 7.45; control group—20.12 ± 12.35
			Control group: levofloxacin + metronidazole tablets	3. HIF-1α : treatment group—1.44 ± 0.95; control group—2.55 ± 1.40